#integrase inhibitor

This from a small study of people who switched from a boosted protease inhibitor to Isentress (raltegravir) or Tivicay (dolutegravir).

More high-quality evidence is needed to determine how this class of HIV medications may affect weight gain.

However, various disparities in such rates—based on race, age and HIV regimen—persist.

People who take integrase inhibitors are less likely to stop them due to health issues.

Tivicay (dolutegravir) is a next-generation integrase inhibitor.

The combo of dolutegravir and lamivudine controlled HIV as well as a triple-drug combo of dolutegravir plus Truvada.

Those on Tybost-boosted Vitekta are more than twice as likely as those taking Tivicay to switch meds because of adverse health events.

A new analysis finds that Gilead Sciences’ updated version of its key antiretroviral tenofovir may not actually offer any safety benefits.

Immune reconstitution inflammatory syndrome (IRIS) can occur when individuals with low CD4 counts begin HIV treatment.

A recent study analyzed kidney parameters among those with HIV who were treated for hep C with the regimen.

The once-daily regimen includes the integrase inhibitor bictegravir plus the contents of Descovy (emtricitabine/tenofovir alafenamide).

Starting treatment within four months of infection also predicted a better resurgence of CD4 cells.

More research is needed to determine the metabolic implications of this apparent association and how it may drive diabetes.

Gilead Sciences’ bictegravir-containing combo also has fewer side effects.